Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis

[1]  R. Savai,et al.  Functional diversity of the TP53 mutome revealed by saturating CRISPR mutagenesis , 2023, bioRxiv.

[2]  Sameh Saber,et al.  Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice , 2023, International journal of molecular sciences.

[3]  Xiaocong Pang,et al.  Targeting integrin pathways: mechanisms and advances in therapy , 2023, Signal Transduction and Targeted Therapy.

[4]  Ying Luo,et al.  HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review) , 2022, Oncology reports.

[5]  M. Oren,et al.  Drugging p53 in cancer: one protein, many targets , 2022, Nature Reviews Drug Discovery.

[6]  R. Savai,et al.  Monitoring autochthonous lung tumors induced by somatic CRISPR gene editing in mice using a secreted luciferase , 2022, Molecular Cancer.

[7]  E. Danen,et al.  Targeting Integrins for Cancer Therapy - Disappointments and Opportunities , 2022, Frontiers in Cell and Developmental Biology.

[8]  A. Stenzinger,et al.  p53 partial loss-of-function mutations sensitize to chemotherapy , 2021, Oncogene.

[9]  S. Macdonald,et al.  Emerging therapeutic opportunities for integrin inhibitors , 2021, Nature reviews. Drug discovery.

[10]  U. Moll,et al.  Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity , 2021, Nature Communications.

[11]  U. Moll,et al.  The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells , 2021, Frontiers in Oncology.

[12]  C. Creighton,et al.  p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi , 2021, Science Advances.

[13]  J. Takagi,et al.  Structural insights into integrin α5β1 opening by fibronectin ligand , 2021, Science Advances.

[14]  A. Marcello,et al.  Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2 , 2021, Viruses.

[15]  S. Lemon,et al.  Iminosugar Glucosidase Inhibitors Reduce Hepatic Inflammation in Hepatitis A Virus-Infected Ifnar1−/− Mice , 2021, Journal of Virology.

[16]  T. Stiewe,et al.  Extracellular Vesicles: Messengers of p53 in Tumor–Stroma Communication and Cancer Metastasis , 2020, International journal of molecular sciences.

[17]  Steven B. Bradfute,et al.  The iminosugars celgosivir, castanospermine and UV-4 inhibit SARS-CoV-2 replication , 2020, Glycobiology.

[18]  C. Creighton,et al.  A pro-tumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma. , 2020, The Journal of clinical investigation.

[19]  N. Alon,et al.  Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome , 2020, Nature Communications.

[20]  T. Butters,et al.  Iminosugars: A host-targeted approach to combat Flaviviridae infections , 2020, Antiviral Research.

[21]  F. Finkernagel,et al.  Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion , 2020, Molecular oncology.

[22]  R. Dwek,et al.  Targeting ER α-glucosidase I with a single-dose iminosugar treatment protects against lethal influenza and dengue virus infections. , 2020, Journal of medicinal chemistry.

[23]  T. Stiewe,et al.  p53’s Extended Reach: The Mutant p53 Secretome , 2020, Biomolecules.

[24]  W. Gu,et al.  Mutant p53 on the Path to Metastasis. , 2020, Trends in cancer.

[25]  The Lancet Haematology,et al.  Proliferation and differentiation. , 2019, The Lancet. Haematology.

[26]  M. Hidalgo,et al.  From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer , 2019, Nature Reviews Clinical Oncology.

[27]  I. Vergote,et al.  Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium , 2019, Front. Oncol..

[28]  G. Lozano.  Restoring p53 in cancer: the promises and the challenges , 2019, Journal of molecular cell biology.

[29]  J. Weinstein,et al.  Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. , 2019, Cell reports.

[30]  Zemin Zhang,et al.  GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis , 2019, Nucleic Acids Res..

[31]  G. Del Sal,et al.  Mutant p53 as a guardian of the cancer cell , 2018, Cell Death & Differentiation.

[32]  J. Norman,et al.  Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels , 2018, Nature Communications.

[33]  F. Greten,et al.  Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. , 2018, Cancer cell.

[34]  Hellyeh Hamidi,et al.  Every step of the way: integrins in cancer progression and metastasis , 2018, Nature Reviews Cancer.

[35]  N. Zitzmann,et al.  Mechanisms of Antiviral Activity of Iminosugars Against Dengue Virus , 2018, Advances in experimental medicine and biology.

[36]  T. Stiewe,et al.  How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[37]  K. Wiman,et al.  Targeting mutant p53 for efficient cancer therapy , 2017, Nature Reviews Cancer.

[38]  G. Lozano,et al.  Mutant p53 partners in crime , 2017, Cell Death and Differentiation.

[39]  S. Goodman,et al.  Integrins as Therapeutic Targets: Successes and Cancers , 2017, Cancers.

[40]  R. Dwek,et al.  Iminosugar antivirals: the therapeutic sweet spot , 2017, Biochemical Society transactions.

[41]  T. Stiewe,et al.  Pro-metastatic p53 mutants control folding of N-glycoproteins , 2017, Cell cycle.

[42]  O. Timofeev,et al.  p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding , 2017, Molecular & cellular oncology.

[43]  G. Lozano,et al.  Mdm proteins: critical regulators of embryogenesis and homoeostasis , 2017, Journal of molecular cell biology.

[44]  Oleg Timofeev,et al.  Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5 , 2016, Proceedings of the National Academy of Sciences.

[45]  U. Moll,et al.  Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy , 2016, Cell Death and Differentiation.

[46]  P. Roversi,et al.  Structures of mammalian ER α-glucosidase II capture the binding modes of broad-spectrum iminosugar antivirals , 2016, Proceedings of the National Academy of Sciences.

[47]  S. Grossman,et al.  Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter , 2016, Oncotarget.

[48]  S. Chien,et al.  Activation of integrin α5 mediated by flow requires its translocation to membrane lipid rafts in vascular endothelial cells , 2016, Proceedings of the National Academy of Sciences.

[49]  J. Caramelo,et al.  A sweet code for glycoprotein folding , 2015, FEBS letters.

[50]  Chengchao Xu,et al.  Glycosylation-directed quality control of protein folding , 2015, Nature Reviews Molecular Cell Biology.

[51]  M. Molinari,et al.  N-linked sugar-regulated protein folding and quality control in the ER. , 2015, Seminars in cell & developmental biology.

[52]  D. Proia,et al.  Improving survival by exploiting tumor dependence on stabilized mutant p53 for treatment , 2015, Nature.

[53]  R. Grosse,et al.  Nuclear F-actin Formation and Reorganization upon Cell Spreading*♦ , 2015, The Journal of Biological Chemistry.

[54]  Feng Yang,et al.  Establishment of an orthotopic pancreatic cancer mouse model: cells suspended and injected in Matrigel. , 2014, World journal of gastroenterology.

[55]  O. Timofeev,et al.  Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases , 2014, Nature Communications.

[56]  T. Soussi,et al.  TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade , 2014, Human mutation.

[57]  Jianmin Wu,et al.  Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling , 2014, Cell.

[58]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[59]  Pedro Carvalho,et al.  ER-associated degradation: Protein quality control and beyond , 2014, The Journal of cell biology.

[60]  B. Luo,et al.  Integrin bi‐directional signaling across the plasma membrane , 2013, Journal of cellular physiology.

[61]  M. Dontenwill,et al.  Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors , 2013, Cancers.

[62]  Carol Prives,et al.  Mutant p53: one name, many proteins. , 2012, Genes & development.

[63]  J. Norman,et al.  Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion , 2012, Oncogene.

[64]  Y. Sugita,et al.  Crystal structure of α5β1 integrin ectodomain: Atomic details of the fibronectin receptor , 2012, The Journal of cell biology.

[65]  J. Norman,et al.  Diacylglycerol kinase α controls RCP-dependent integrin trafficking to promote invasive migration , 2012, The Journal of cell biology.

[66]  M. Ginsberg,et al.  Regulation of integrin activation. , 2011, Annual review of cell and developmental biology.

[67]  F. Talos,et al.  Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells , 2011, Molecular Cancer Research.

[68]  Jason I. Herschkowitz,et al.  The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo , 2011, Proceedings of the National Academy of Sciences.

[69]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[70]  Tak W. Mak,et al.  The ER UDPase ENTPD5 Promotes Protein N-Glycosylation, the Warburg Effect, and Proliferation in the PTEN Pathway , 2010, Cell.

[71]  J. Caramelo,et al.  UDP-GlC:glycoprotein glucosyltransferase-glucosidase II, the ying-yang of the ER quality control. , 2010, Seminars in cell & developmental biology.

[72]  Paul Timpson,et al.  Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.

[73]  J. Norman,et al.  Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.

[74]  J. Norman,et al.  Integrins: masters and slaves of endocytic transport , 2009, Nature Reviews Molecular Cell Biology.

[75]  Wensheng Yan,et al.  Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function* , 2009, Journal of Biological Chemistry.

[76]  R. Kutner,et al.  Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors , 2009, Nature Protocols.

[77]  Pauline M Rudd,et al.  The conformational properties of the Glc3Man unit suggest conformational biasing within the chaperone-assisted glycoprotein folding pathway. , 2009, Journal of molecular biology.

[78]  T. Iwakuma,et al.  The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. , 2008, Genes & development.

[79]  J. Dennis,et al.  Complex N-Glycan Number and Degree of Branching Cooperate to Regulate Cell Proliferation and Differentiation , 2007, Cell.

[80]  S. Lovell,et al.  ERp57 is essential for efficient folding of glycoproteins sharing common structural domains , 2007, The EMBO journal.

[81]  J. Marth,et al.  Glycosylation in Cellular Mechanisms of Health and Disease , 2006, Cell.

[82]  David B. Williams.  Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum , 2006, Journal of Cell Science.

[83]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[84]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[85]  A. Helenius,et al.  Roles of N-linked glycans in the endoplasmic reticulum. , 2004, Annual review of biochemistry.

[86]  Meng Yang,et al.  Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. , 2002, Cancer research.

[87]  P. Montgomery,et al.  Acarbose: an alpha-glucosidase inhibitor. , 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[88]  A Helenius,et al.  How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum. , 1994, Molecular biology of the cell.

[89]  H. Ahr,et al.  Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man. , 1989, Arzneimittel-Forschung.

[90]  D. Lane,et al.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others , 2018, Nature Reviews Clinical Oncology.

[91]  G. Su,et al.  Development of orthotopic pancreatic tumor mouse models. , 2013, Methods in molecular biology.

[92]  A. Helenius,et al.  Protein oligomerization in the endoplasmic reticulum. , 1989, Annual review of cell biology.